Sentences with phrase «cell therapy system»

With those collaborations, our goal is to develop and eventually integrate the QuickGel platform into these closed cell therapy systems, allowing us to meet the scale and efficiency demands of the clinical bioprocess.

Not exact matches

For example, we've seen new discoveries in health care recently, especially in immuno - oncology therapies, which help the immune systems of cancer patients recognize and destroy cancerous cells.

During the sessions, U.S. and Cuban scientists explored such topics as the molecular mechanisms cancer cells employ to evade the body's immune system, new tools to image and manipulate that system, and ways to rethink how such therapies can best be deployed to reach patients where they receive health services.

A group of the nation's leading cancer research scientists and their Cuban counterparts are exploring how to advance cancer therapy, diagnosis, and prevention, including the use of immunotherapy to harness the body's immune systems to attack and eliminate cancer cells.

A type of immune therapy known as PD - 1 blockade controlled cancer in 77 percent of patients with defects in DNA mismatch repair — the system cells use to spell - check and fix errors in DNA (SN Online: 10/7/15).

«Current therapies in clinical trials are focused on targeting genetic changes in tumors and helping to boost one's immune system to fight the cancer cells.

We believe that they will also lead to the development of a whole new range of therapies for neurodegenerative diseases of the central nervous system,» explains corresponding author of the study Jihwan Song, professor and director of Neural Regeneration and Therapy Group at the CHA Stem Cell Institute of CHA University.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

But scientists are making progress in refining these therapies, and the first ever trial of fetal stem cells injected directly into the brain is currently under way in children with Batten disease, a rare and fatal illness of the nervous system.

Antibodies and T cells against the protein could cause the immune system to attack cells carrying it, making gene therapy ineffective.

And early stage startup Neochromosome, which includes Boeke, intends to raise money to design synthetic chromosomes for medicine that could be used in an off - the - shelf universal cell line in cell therapies and transplants with minimal risk of rejection from the immune system.

«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.

EMD Serono, Kirschbaum says, «focuses on the development of targeted cancer therapies on three therapeutic platforms: targeting the tumor cell, the tumor environment, and the immune system.»

Researchers are developing many different versions of CAR - T cell therapies, but the basic premise is the same: Doctors remove a patient's T cells (immune system cells that attack invaders) from a blood sample and genetically modify them to produce artificial proteins on their surfaces.

HIV also hides in cells and continues to undermine the host's immune system despite antiretroviral therapy that has improved the outlook of those with AIDS.

A phase 3 trial of lenalidomide / dexamethasone with elotuzumab (Empliciti ™), an antibody therapy that attacks myeloma cells directly and spurs the immune system to launch an attack of its own.

With additional genome tinkering to avoid rejection by the immune system, they could be used clinically as a universal stem cell therapy.

My cancer systems biology team at the University of California, Merced, is tackling diagnosis and treatment of therapy - resistant cancers by elucidating the network of changes within cells as a way to identify new drug targets and circumvent cancer resistance.

Dr. Cripe and his colleagues at The Ohio State University, the University of Pittsburgh School of Medicine and Cincinnati Children's Hospital Medical Center tested how well the oncolytic viral therapy — a cancer - killing form of the herpes simplex virus, called oHSV — infected and killed tumor cells in mice with and without a healthy immune system.

Epigenetic therapies are thought to work in two ways to fix these errors in cancer cells — by correcting the «position» of the gene switches and by making the cell appear as though it's infected by a virus, triggering the immune system.

According to Dr. Cripe, the study suggests that some patients could respond to therapy even if their tumors aren't very infectable by the virus, provided their immune systems were stimulated by the viral therapy to attack the tumor cells.

Immune therapy for ovarian, breast and colorectal cancer — treatments that encourage the immune system to attack cancer cells as the foreign invaders they are — has so far had limited success, primarily because the immune system often can't destroy the cancer cells.

Treatment with an investigational CAR T - cell therapy induced complete remission of a brain metastasis of the difficult - to - treat tumor diffuse large - B - cell lymphoma (DLBCL), which had become resistant to chemotherapy — the first report of a response to CAR T - cells in a central nervous system lymphoma.

«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical School.

«Research into basic workings of immune system points to way of improving therapies for cancer: Differences in wiring of «exhausted» and effective T cells indicate possible gene - editing targets.»

These cells, in turn, instruct factor - VIII — specific immune cells to become tolerant to the coagulation protein, resulting in suppression of misdirected antibody responses to the replacement therapy — all without affecting the rest of the immune system.

Thermal fluids are used to alleviate wear on components and tools and for machining operations like stamping and drilling, medical therapy and diagnosis, biopharmaceuticals, air conditioning, fuel cells, power transmission systems, solar cells, micro - and nanoelectronic mechanical systems and cooling systems for everything from engines to nuclear reactors.

Kole Roybal is the 2018 grand prize winner of the inaugural Sartorius & Science Prize for Regenerative Medicine & Cell Therapy, for developing a new class of T cell immunotherapies that can be fine - tuned to better help the immune system recognize cancer and initiate precise therapeutic action against the diseCell Therapy, for developing a new class of T cell immunotherapies that can be fine - tuned to better help the immune system recognize cancer and initiate precise therapeutic action against the disecell immunotherapies that can be fine - tuned to better help the immune system recognize cancer and initiate precise therapeutic action against the disease.

There are experiments in using stock market — like systems, in which people bet on ideas to answer seemingly unanswerable questions, like when terrorist events will occur or when stem cell therapy will allow a person to grow new teeth.

The prospect of combining genomically targeted therapies with drugs that free the immune system to attack cancer suggests «we are finally poised to deliver curative therapies to cancer patients,» researchers at The University of Texas MD Anderson Cancer Center note in a review in the April 9 edition of Cell.

The two cell types are important to a broad range of organ systems in the body and play active roles in diseases that could be targets for nucleic acid therapies.

This discovery lays the groundwork for a better understanding of the role progenitor cells can play in immune system response and could lead to the development of more effective therapies for a wide range of diseases.

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

And, in fact, these doctors and researchers are finding incredible success with this strategy; for example, PD - 1 inhibitors remove this «cloak» that cancers use to hide from the immune system, and CAR - T cell therapies use specially engineered T - cells to seek cancer - specific proteins and destroy the cancer cells to which they are attached.

They lie dormant and can not be eliminated by anti-retroviral therapy, nor by the weakened immune system, so that if treatment is stopped at any time, the virus starts to replicate and infect more cells again, while the immune system can not suppress this rebound of HIV infection.

«New way to unmask melanoma cells to the immune system: Lab studies show promise for a clinical trial aimed at improving current immune therapies.»

But while we have decades of data in mice about these nervous system support cells, how relevant those experiments are to human biology (and the success of potential therapies) has been an open question.

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

The technique «potentially provides ways to create model systems for studying the genetic basis of diabetes, or to discover novel therapies to enhance existing β cells,» Ferrer says.

The moves also include # 50 million ($ 78 million) for a London - based «cell therapy technology and innovation center,» and # 60 million ($ 93 million) to develop the secure system that would allow researchers access to anonymized patient data from the National Health Service (NHS).

Instead, we administer a combination therapy to allow immune cells, which are capable of killing tumors, to see tumors that were previously invisible to the immune system.»

Checkpoint blockade therapy obstructs those signals, makes T - cells see the cancer cells as invaders again, and allows the immune system to do its job.

But if the immune system is involved in the new - found problems, it provides additional impetus to develop «personalised» therapies, in which neurons are grown from a patient's own cells, and so should be less likely to provoke an immune reaction.

Lastly, two sessions dedicated to disease modeling and cell therapy, respectively, will highlight ongoing attempts to study and treat diseases using stem cells from the hematopoietic and neural systems.

Geneva, Switzerland, 26 March 2014 — A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

An alternative approach is to persuade the immune system to attack tumours, using vaccines, biological therapies such as alpha interferon or interleukin 2 and genetically altered white blood cells.

This work was supported by the Max - Planck - Society, the German Research Council (DFG), the Excellence Cluster Cardiopulmonary System (ECCPS), the University of Giessen - Marburg Lung Center (UGMLC), the Cell and Gene Therapy Center (CGT) of the University of Frankfurt and the EY10540 grant to PAT.

The advent of molecular cloning, DNA sequencing and the many tools of molecular genetics and cell biology has given us sufficient knowledge of the basis for disease and the genes to target, but what has limited the application of gene therapy has been efficient gene delivery systems.

An international research team led by Université de Montréal medical professor Christopher Rudd, director of research in immunology and cell therapy at Maisonneuve - Rosemont Hospital Research Centre, has identified a key new mechanism that regulates the ability of T - cells of the immune system to react against foreign antigens and cancer.

Other research at U-M is developing new options for treating brain cancer through immunotherapy — harnessing the immune system to attack cancer cells once an injection of a particular gene therapy is delivered into the brain tumor.